Streetbeat News

Stock Prices

FIXX

Homology Medicines Inc (NASDAQ:FIXX) announced initial data from its pheEDIT Phase 1 trial, showing positive results. However, due to the current financing environment and anticipated clinical development timelines, Homology will not be further developing its programs and will be reducing its workforce by 87%. The company has retained TD Cowen as its strategic financial advisor. These measures are expected to extend Homology's cash runway into 2026. As of March 31, 2023, Homology had approximately $150.0 million in cash, cash equivalents, and short-term investments. FIXX shares are up 23.40% at $1.16 during the premarket session on the last check Friday.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 1:14 pm

DECK

Deckers Outdoor reported Q1 financial results and issued FY24 revenue outlook below estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 1:13 pm

CL

Colgate-Palmolive Company (NYSE:CL) reported Q2 FY23 sales growth of 7.5% YoY to $4.82 billion, beating the consensus of $4.67 billion. Non-GAAP EPS of $0.77 beat the analyst consensus of $0.75. The company sees strong investment levels to continue in the back half of the year to deliver balanced organic sales growth. However, CL shares are trading lower by 1.58% at $75.89 in premarket.

Portfolio Pulse from Nabaparna Bhattacharya

July 28, 2023 | 1:13 pm

TTD

The Trade Desk's stock has been upgraded from Neutral to Buy by BTIG, with a new price target of $103. This has resulted in the shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 1:11 pm

SAIA

Saia Inc. reported better-than-expected Q2 earnings per share (EPS), leading to a rise in its stock price.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 1:09 pm

BEN

Franklin Resources has reported its Q3 financial results, which has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 1:08 pm

ASML

CHTR

GM

LYV

Charter Communications (CHTR) is set to release quarterly earnings on July 28, 2023, and is trading at 10 times earnings. ASML Holding (ASML) reported better-than-expected Q2 results and issued cautious Q3 guidance. General Motors (GM) reported a beat and raise quarter, with the stock returning to its pre-earnings report level. Live Nation Entertainment (LYV) reported better-than-expected Q2 financial results.

Portfolio Pulse from Lisa Levin

July 28, 2023 | 1:08 pm

BIIB

RETA

Biogen Inc has agreed to acquire Reata Pharmaceuticals Inc for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata's FDA-approved Skyclarys is the first and only approved treatment for Friedreich's ataxia in the U.S. The acquisition is expected to close in Q4 2023 and is expected to be slightly dilutive to Biogen's Non-GAAP diluted EPS in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 1:07 pm

TROW

T. Rowe Price Group reported better-than-expected Q2 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 1:07 pm

COUR

SG

SNBR

UFAB

In Friday's pre-market session, several consumer discretionary stocks saw significant movement. Gainers included Unique Fabricating (UFAB), Coursera (COUR), Tupperware Brands (TUP), ECARX Holdings (ECX), Jakks Pacific (JAKK), and Dana (DAN), with increases ranging from 6.27% to 71.3%. Losers included Sleep Number (SNBR), Sweetgreen (SG), SunCar Tech Gr (SDA), Yoshiharu Global (YOSH), China Liberal Education (CLEU), and ThredUp (TDUP), with decreases ranging from 4.84% to 26.0%.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 1:06 pm